CA-125 (cancer antigen 125, carcinoma antigen 125, or carbohydrate antigen 125) also known as mucin 16 or MUC16 is a protein that in humans is encoded by the MUC16gene. MUC16 is a member of the mucin family glycoproteins. CA-125 has found application as a tumor marker or biomarker that may be elevated in the blood of some patients with specific types of cancers, or other conditions that are benign.
Mucin 16 is a membrane associated mucin that possesses a single transmembrane domain. A unique property of MUC16 is its large size. MUC16 is more than twice as long as MUC1 and MUC4 and contains about 22,000 amino acids, making it the largest membrane-associated mucin.
The N-terminal and tandem repeat domains are both entirely extracellular and highly O-glycosylated. All mucins contain a tandem repeat domain that has repeating amino acid sequences high in serine, threonine and proline. The C-terminal domain contains multiple extracellular SEA (sea urchin sperm protein, enterokinase, and agrin) modules, a transmembrane domain, and a cytoplasmic tail. The extracellular region of MUC16 can be released from the cell surface by undergoing proteolytic cleavage. MUC16 is thought to be cleaved at a site in the SEA modules.
Around 90% of women with advanced ovarian cancer have elevated levels of CA-125 in their blood serum, making CA-125 a useful tool for detecting ovarian cancer after the onset of symptoms. Monitoring CA-125 blood serum levels is also useful for determining how ovarian cancer is responding to treatment (with the duration of disease-free survival correlating with the rate of fall of CA-125) and for predicting a patient’s prognosis after treatment. This is because the persistence of high levels of CA-125 during therapy is associated with poor survival rates in patients. Also, an increase in CA-125 levels within individuals in a remission is a strong predictor of the recurrence of ovarian cancer. Indeed, a rising CA-125 level may precede clinical evidence of disease relapse by an interval of 3 to 6 months.
Prognosis relates to both the initial and post-treatment CA-125 values. A preoperative value >65 U/mL suggests a poor prognosis. Persistent elevations following chemotherapy indicate a poor prognosis. The half-life of CA-125 after chemotherapy correlates with prognosis (patients with CA-125 half-life <20 days show improved survival). Time-to-normalization (rate of fall of CA-125) affects prognosis with more rapid normalization within 3 cycles of chemotherapy correlating with improved survival.
In April 2011 the UK's National Institute for Health and Clinical Excellence (NICE) recommended that women with symptoms that could be caused by ovarian cancer should be offered a CA-125 blood test. The aim of this guideline is to help diagnose the disease at an earlier stage, when treatment is more likely to be successful. Women with higher levels of the marker in their blood would then be offered an ultrasound scan to determine whether they need further tests.
In one case, elevated serum levels of CA-125 were observed in a male patient with IgE myeloma, however more cases are needed to determine the clinical significance of CA-125 in myeloma.
Early detection of ovarian cancer
The potential role of CA-125 for the early detection of ovarian cancer is controversial and has not yet been adopted for widespread screening efforts in asymptomatic women. The major issues with using the CA-125 biomarker are its lack of sensitivity, particularly for detecting early stages of ovarian cancer, and its lack of specificity, especially in premenopausal women. These limitations mean that CA-125 testing often gives false positives for ovarian cancer and puts patients through unnecessary further screening (sometimes including surgery) and anxiety. Also, these limitations mean that many women with early stage ovarian cancer will receive a false negative from CA-125 testing and not get further treatment for their condition.
The specificity of CA-125 is particularly low in premenopausal women because many benign conditions that cause fluctuations in CA-125 levels, such as menstruation, pregnancy, and pelvic inflammatory disease, are seen in this population.
CA-125 testing is also not perfectly sensitive for detecting ovarian cancer because not every patient with cancer will have elevated levels of CA-125 in their blood. For example, 79% of all ovarian cancers are positive for CA-125, whereas the remainder do not express this antigen at all. Also, only about 50% of patients with early stage ovarian cancer have elevated CA-125 levels, meaning that CA-125 has particularly poor sensitivity for ovarian cancer before the onset of symptoms. Poor sensitivity means that the use of CA-125 to detect ovarian cancer (especially in early stages of disease) can frequently lead to false negatives. Patients that receive false negatives are unlikely to seek further treatment for their disease.
Ranges in ovarian cancer
While this test is not generally regarded as useful for large scale screening by the medical community, a high value may be an indication that the woman should receive further diagnostic screening or treatment. Normal values range from 0 to 35 (U/mL). Elevated levels in post-menopausal women are usually an indication that further screening is necessary. In pre-menopausal women, the test is less reliable as values are often elevated due to a number of non-cancerous causes, and a value above 35 is not necessarily a cause for concern.
In a patient who is clinically selected for testing due to the presence of an adnexal/pelvic mass, CA-125 has great utility to differentiate benign from malignant processes. In a post-menopausal woman with a palpable adnexal mass and CA-125 level greater than 65 U/mL, the positive predictive value is >95% for ovarian malignancy. In patients who are not as carefully selected clinically, the utility of this test decreases, thus highlighting the need for careful clinical scrutiny.
Role in cancer
Tumor metastasis initiated by interactions between MUC16 and mesothelin.
MUC16 (CA-125) has been shown to play a role in advancing tumorigenesis and tumor proliferation by several different mechanisms.
Immune system evasion
One way that MUC16 helps the growth of tumors is by suppressing the response of natural killer cells, thereby protecting cancer cells from the immune response. Further evidence that MUC16 can protect tumor cells from the immune system is the discovery that the heavily glycosylatedtandem repeat domain of MUC16 can bind to galectin-1 (an immunosuppressive protein).
MUC16 is also thought to participate in cell-to-cell interactions that enable the metastasis of tumor cells. This is supported by evidence showing that MUC16 binds selectively to mesothelin, a glycoprotein normally expressed by the mesothelial cells of the peritoneum (the lining of the abdominal cavity). MUC16 and mesothelin interactions are thought to provide the first step in tumor cell invasion of the peritoneum.
Mesothelin has also been found to be expressed in several types of cancers including mesothelioma, ovarian cancer and squamous cell carcinoma. Since mesothelin is also expressed by tumor cells, MUC16 and mesothelial interactions may aid in the gathering of other tumor cells to the location of a metastasis, thus increasing the size of the metastasis.
Evidence suggests that expression of the cytoplasmic tail of MUC16 enables tumor cells to grow, promotes cell motility and may facilitate invasion. This appears to be due to the ability of the C-terminal domain of MUC16 to facilitate signaling that leads to a decrease in the expression of E-cadherin and increase the expression of N-cadherin and vimentin, which are expression patterns consistent with epithelial-mesenchymal transition.
MUC16 may also play a role in reducing the sensitivity of cancer cells to drug therapy. For example, overexpression of MUC16 has been shown to protect cells from the effects of genotoxic drugs, such as cisplatin.
CA-125 was initially detected using the murinemonoclonal antibody designated OC125. Robert Bast, Robert Knapp and their research team first isolated this monoclonal antibody in 1981. The protein was named “cancer antigen 125” because OC125 was the 125th antibody produced against the ovarian cancer cell line that was being studied.
^Yin BW, Lloyd KO (Jul 2001). "Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16". The Journal of Biological Chemistry. 276 (29): 27371–5. doi:10.1074/jbc.M103554200. PMID11369781.
^Yin BW, Dnistrian A, Lloyd KO (Apr 2002). "Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene". International Journal of Cancer. 98 (5): 737–40. doi:10.1002/ijc.10250. PMID11920644.
^Duraisamy S, Ramasamy S, Kharbanda S, Kufe D (May 2006). "Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16". Gene. 373: 28–34. doi:10.1016/j.gene.2005.12.021. PMID16500040.
^ abBast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB (1998). "CA 125: the past and the future". The International Journal of Biological Markers. 13 (4): 179–87. PMID10228898.
^ abO'Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L (Nov–Dec 2001). "The CA 125 gene: an extracellular superstructure dominated by repeat sequences". Tumour Biology. 22 (6): 348–66. doi:10.1159/000050638. PMID11786729.
^Hollingsworth MA, Swanson BJ (Jan 2004). "Mucins in cancer: protection and control of the cell surface". Nature Reviews. Cancer. 4 (1): 45–60. doi:10.1038/nrc1251. PMID14681689.
^Palmai-Pallag T, Khodabukus N, Kinarsky L, Leir SH, Sherman S, Hollingsworth MA, Harris A (Jun 2005). "The role of the SEA (sea urchin sperm protein, enterokinase and agrin) module in cleavage of membrane-tethered mucins". The FEBS Journal. 272 (11): 2901–11. doi:10.1111/j.1742-4658.2005.04711.x. PMID15943821.
^Suh KS, Park SW, Castro A, Patel H, Blake P, Liang M, Goy A (Nov 2010). "Ovarian cancer biomarkers for molecular biosensors and translational medicine". Expert Review of Molecular Diagnostics. 10 (8): 1069–83. doi:10.1586/erm.10.87. PMID21080822.
"Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer". Obstetrics and Gynecology. 117 (3): 742–6. Mar 2011. doi:10.1097/AOG.0b013e31821477db. PMID21343791.
^Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC (Oct 1983). "A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer". The New England Journal of Medicine. 309 (15): 883–7. doi:10.1056/NEJM198310133091503. PMID6310399.
^ abGöcze P, Vahrson H (Apr 1993). "[Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies)]". Orvosi Hetilap (in Hungarian). 134 (17): 915–8. PMID8479736.
^ abSantillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL, Armstrong DK, Bristow RE (Dec 2005). "Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range". Journal of Clinical Oncology. 23 (36): 9338–43. doi:10.1200/JCO.2005.02.2582. PMID16361633.
^Mais DD, Leonard GR (2009). Quick Compendium Companion for Clinical Pathology (2nd ed.). Chicago: American Society for Clinical Pathology. p. 352. ISBN0-89189-579-5.
^ abcFritsche HA, Bast RC (Jul 1998). "CA 125 in ovarian cancer: advances and controversy". Clinical Chemistry. 44 (7): 1379–80. PMID9665412.
^ abcdeNossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST, Farias-Eisner R (Sep 2008). "The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?". American Journal of Obstetrics and Gynecology. 199 (3): 215–23. doi:10.1016/j.ajog.2008.04.009. PMID18468571.
^Osman N, O'Leary N, Mulcahy E, Barrett N, Wallis F, Hickey K, Gupta R (Sep 2008). "Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre". Irish Medical Journal. 101 (8): 245–7. PMID18990955.
^Bagan P, Berna P, Assouad J, Hupertan V, Le Pimpec Barthes F, Riquet M (Jan 2008). "Value of cancer antigen 125 for diagnosis of pleural endometriosis in females with recurrent pneumothorax". The European Respiratory Journal. 31 (1): 140–2. doi:10.1183/09031936.00094206. PMID17804443.
^Sarandakou A, Protonotariou E, Rizos D (2007). "Tumor markers in biological fluids associated with pregnancy". Critical Reviews in Clinical Laboratory Sciences. 44 (2): 151–78. doi:10.1080/10408360601003143. PMID17364691.
^Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC (Nov 2005). "Potential markers that complement expression of CA125 in epithelial ovarian cancer". Gynecologic Oncology. 99 (2): 267–77. doi:10.1016/j.ygyno.2005.06.040. PMID16061277.
^Patankar MS, Jing Y, Morrison JC, Belisle JA, Lattanzio FA, Deng Y, Wong NK, Morris HR, Dell A, Clark GF (Dec 2005). "Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125". Gynecologic Oncology. 99 (3): 704–13. doi:10.1016/j.ygyno.2005.07.030. PMID16126266.
^Seelenmeyer C, Wegehingel S, Lechner J, Nickel W (Apr 2003). "The cancer antigen CA125 represents a novel counter receptor for galectin-1". Journal of Cell Science. 116 (Pt 7): 1305–18. doi:10.1242/jcs.00312. PMID12615972.
^Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A (Mar 2004). "Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion". The Journal of Biological Chemistry. 279 (10): 9190–8. doi:10.1074/jbc.M312372200. PMID14676194.
^Thériault C, Pinard M, Comamala M, Migneault M, Beaudin J, Matte I, Boivin M, Piché A, Rancourt C (Jun 2011). "MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis". Gynecologic Oncology. 121 (3): 434–43. doi:10.1016/j.ygyno.2011.02.020. PMID21421261.
^Boivin M, Lane D, Piché A, Rancourt C (Dec 2009). "CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis". Gynecologic Oncology. 115 (3): 407–13. doi:10.1016/j.ygyno.2009.08.007. PMID19747716.
Dogru M, Matsumoto Y, Okada N, Igarashi A, Fukagawa K, Shimazaki J, Tsubota K, Fujishima H (Oct 2008). "Alterations of the ocular surface epithelial MUC16 and goblet cell MUC5AC in patients with atopic keratoconjunctivitis". Allergy. 63 (10): 1324–34. doi:10.1111/j.1398-9995.2008.01781.x. PMID18782111.
McLemore MR, Aouizerat B (Apr 2005). "Introducing the MUC16 gene: implications for prevention and early detection in epithelial ovarian cancer". Biological Research for Nursing. 6 (4): 262–7. doi:10.1177/1099800404274445. PMID15788735.
Palmieri RT, Wilson MA, Iversen ES, Clyde MA, Calingaert B, Moorman PG, Poole C, Anderson AR, Anderson S, Anton-Culver H, Beesley J, Hogdall E, Brewster W, Carney ME, Chen X, Chenevix-Trench G, Chang-Claude J, Cunningham JM, Dicioccio RA, Doherty JA, Easton DF, Edlund CK, Gayther SA, Gentry-Maharaj A, Goode EL, Goodman MT, Kjaer SK, Hogdall CK, Hopkins MP, Jenison EL, Blaakaer J, Lurie G, McGuire V, Menon U, Moysich KB, Ness RB, Pearce CL, Pharoah PD, Pike MC, Ramus SJ, Rossing MA, Song H, Terada KY, Vandenberg D, Vierkant RA, Wang-Gohrke S, Webb PM, Whittemore AS, Wu AH, Ziogas A, Berchuck A, Schildkraut JM (Dec 2008). "Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women". Cancer Epidemiology, Biomarkers & Prevention. 17 (12): 3567–72. doi:10.1158/1055-9965.EPI-08-0548. PMC2664299. PMID19064572.
Sangoi AR, Higgins JP, Rouse RV, Schneider AG, McKenney JK (May 2009). "Immunohistochemical comparison of MUC1, CA125, and Her2Neu in invasive micropapillary carcinoma of the urinary tract and typical invasive urothelial carcinoma with retraction artifact". Modern Pathology. 22 (5): 660–7. doi:10.1038/modpathol.2009.16. PMID19270645.
Bekci TT, Senol T, Maden E (2009). "The efficacy of serum carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 15-3 (CA15-3), alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG) levels in determining the malignancy of solitary pulmonary nodules". The Journal of International Medical Research. 37 (2): 438–45. doi:10.1177/147323000903700219. PMID19383238.
Bjerner J, Høgetveit A, Wold Akselberg K, Vangsnes K, Paus E, Bjøro T, Børmer OP, Nustad K (2008). "Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study". Scandinavian Journal of Clinical and Laboratory Investigation. 68 (8): 703–13. doi:10.1080/00365510802126836. PMID18609108.
Madendag Y, Col-Madendag I, Kanat-Pektas M, Danisman N (May 2009). "Predictive power of serum CA-125 and LDH in the outcome of first trimester pregnancies with human chorionic gonadotropin levels below discriminatory zone". Archives of Gynecology and Obstetrics. 279 (5): 661–6. doi:10.1007/s00404-008-0798-x. PMID18797897.
Camlica H, Duranyildiz D, Tas F, Yasasever V (Dec 2008). "Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer". American Journal of Clinical Oncology. 31 (6): 585–8. doi:10.1097/COC.0b013e318174dbd2. PMID19060592.
Prat A, Parera M, Adamo B, Peralta S, Perez-Benavente MA, Garcia A, Gil-Moreno A, Martinez-Palones JM, Baselga J, del Campo JM (Feb 2009). "Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels". Annals of Oncology. 20 (2): 294–7. doi:10.1093/annonc/mdn601. PMID18820245.
de Larrea CF, Cibeira MT, Vallansot R, Colomo L, Bladé J (Oct 2008). "Increased serum tumor markers (CA125 and CA15.3) in primary plasma cell leukemia: a case report and review of the literature". Clinical Lymphoma & Myeloma. 8 (5): 312–4. doi:10.3816/CLM.2008.n.045. PMID18854288.
Yu B, Xu PZ, Wang QW, Zhou H, Zhou HX (2009). "Clinical value of tumour specific growth factor (TSGF) and carbohydrate antigen-125 (CA-125) in carcinoma of the endometrium". The Journal of International Medical Research. 37 (3): 878–83. doi:10.1177/147323000903700333. PMID19589273.
Kouba EJ, Lentz A, Wallen EM, Pruthi RS (2009). "Clinical use of serum CA-125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder". Urologic Oncology. 27 (5): 486–90. doi:10.1016/j.urolonc.2008.03.019. PMID18555706.
Samuels TL, Handler E, Syring ML, Pajewski NM, Blumin JH, Kerschner JE, Johnston N (Sep 2008). "Mucin gene expression in human laryngeal epithelia: effect of laryngopharyngeal reflux". The Annals of Otology, Rhinology, and Laryngology. 117 (9): 688–95. doi:10.1177/000348940811700911. PMID18834073.
De Gennaro L, Brunetti ND, Bungaro R, Montrone D, Cuculo A, Pellegrino PL, Correale M, Di Biase M (Jun 2009). "Carbohydrate antigen-125: additional accuracy in identifying patients at risk of acute heart failure in acute coronary syndrome". Coronary Artery Disease. 20 (4): 274–80. doi:10.1097/MCA.0b013e3283229d82. PMID19440066.